Quaternized Lipid Nanoassemblies: Redirecting mRNA Delivery from Spleen to Lung

Study Background and Research Question

Lipid nanoparticles (LNPs) have become central to the systemic delivery of nucleic acids, including mRNA, in both research and clinical applications. However, a critical limitation persists: after intravenous administration, most LNPs preferentially accumulate in the liver, restricting their utility for extrahepatic targets. This hepatic tropism is mainly attributed to apolipoprotein E adsorption and LDLR-mediated hepatocyte uptake. As the need for non-liver targeted mRNA delivery platforms grows, researchers seek strategies that can reliably redirect mRNA expression to specific organs without increasing formulation complexity or relying on targeting ligands. The study by Huang et al. (Theranostics, 2024) addresses this challenge by investigating whether structural modification—specifically, quaternization—of lipid-like nanoassemblies can reprogram organ tropism and achieve lung-specific mRNA delivery.

Key Innovation from the Reference Study

The principal breakthrough reported by Huang et al. lies in the application of a N-quaternizing strategy to a previously developed lipid-like compound (tB-UC18), producing a cationic variant termed qtB-UC18. While unmodified tB-UC18/DOPE nanoassemblies deliver mRNA mainly to the spleen, the introduction of quaternary ammonium groups completely shifts tropism to the lung. Notably, this transformation does not require the addition of targeting ligands or complex formulation changes, representing a significant simplification of lung-targeted mRNA delivery.

Methods and Experimental Design Insights

The research team synthesized qtB-UC18 by methylating the secondary amines of tB-UC18 using iodomethane. This structural change endowed the lipid-like molecule with a permanently charged (cationic) head group. Nanoassemblies were then formed by combining qtB-UC18 with the helper lipid DOPE, encapsulating model mRNAs for reporter expression studies. The physicochemical properties of these nanoassemblies, such as particle size and surface charge, were characterized. In vitro mRNA delivery efficiency was assessed in cell culture, while in vivo organ tropism was measured following intravenous injection in mice. Fluorescence imaging and tissue analysis quantified reporter mRNA expression across organs, allowing precise mapping of delivery outcomes.

Protocol Parameters

• Quaternization Reaction: N-alkylation of tB-UC18 with iodomethane to obtain qtB-UC18; reaction conditions as optimized in the reference study.
• Nanoassembly Formation: Combine qtB-UC18 and DOPE at defined molar ratios (as per Huang et al.); encapsulate in vitro transcribed mRNA reporter constructs.
• In Vivo Delivery: Intravenous administration in mice; monitor organ-specific expression via imaging and tissue analysis at designated time points.
• Stability Assessment: Storage of formulated nanoassemblies at room temperature for over one year; test for delivery activity post-storage.
• Reporter mRNA Selection: Use of enhanced green fluorescent protein mRNA or equivalent for quantifiable expression readout.

Core Findings and Why They Matter

Huang et al. demonstrated that quaternized LLNs (qtB-UC18/DOPE) delivered mRNA almost exclusively to the lungs after systemic injection, with >95% of exogenous mRNA translation occurring in pulmonary tissue (see study). This was in stark contrast to the spleen-selective delivery observed with the parent tB-UC18 assemblies. Cellular uptake studies revealed a predominant localization within pulmonary immune cells, suggesting potential for both gene expression studies and therapeutic interventions targeting the lung immune microenvironment. Importantly, the quaternized assemblies retained their delivery efficacy after more than one year of ambient storage, underscoring their practical robustness.

This approach bypasses the need for targeting ligands or complex formulation adjustments, providing a streamlined method for lung-specific mRNA delivery. For researchers focused on pulmonary gene therapy, immune modulation, or in vivo imaging with fluorescent mRNA, this technique substantially broadens the experimental and therapeutic landscape.

Comparison with Existing Internal Articles

Several internal resources, such as "Engineering the Future of Translational mRNA Research" and "Applied Workflows with EZ Cap EGFP mRNA 5-moUTP", provide guidance on optimizing mRNA delivery for robust gene expression, immune evasion, and in vivo imaging. These guides emphasize the role of advanced mRNA engineering—such as Cap 1 structures and 5-moUTP modifications—in enhancing translation efficiency and suppressing RNA-mediated innate immune activation.

The reference study complements these insights by demonstrating that delivery vehicle design, especially quaternization, can be as pivotal as mRNA engineering in dictating tissue specificity. While the internal articles focus on maximizing translation and minimizing immunogenicity at the molecular level, Huang et al. show how nanoassembly surface chemistry can fundamentally redirect where and how efficiently mRNA is expressed in vivo. Together, these approaches inform a holistic strategy for mRNA delivery: optimizing both the message and the messenger.

Limitations and Transferability

While the quaternization strategy achieved remarkable lung specificity in mice, several considerations must be addressed before broad application:

• Species differences in nanoparticle biodistribution may limit direct translation to humans.
• Reporter mRNA (e.g., enhanced green fluorescent protein mRNA) may not fully represent the behavior of therapeutic mRNAs, especially those encoding immunomodulatory or secreted proteins.
• Potential long-term effects or pulmonary toxicity of repeated administration of quaternized LLNs remain to be established.
• While suppression of RNA-mediated innate immune activation is possible with optimized mRNA constructs, the immunogenicity of the delivery vehicle itself should be systematically evaluated.

Nevertheless, the simplicity and efficacy of the approach offer a strong foundation for further preclinical development and adaptation to other organ targets by analogous chemical modifications.

Research Support Resources

To facilitate translation of these findings into experimental practice, researchers require reliable reporter mRNAs that maximize translation efficiency and minimize confounding immune responses. EZ Cap™ EGFP mRNA (5-moUTP) (SKU R1016) from APExBIO provides a ready-to-use, Cap 1-structured, 5-methoxyuridine-modified mRNA for robust gene expression studies, translation efficiency assays, and in vivo imaging with fluorescent mRNA. This reagent is compatible with a wide range of delivery systems, including lipid-like nanoassemblies as described by Huang et al., and is suited for workflows requiring high stability and suppression of innate immune activation. For detailed optimization strategies and experimental workflows, readers are encouraged to consult the referenced internal articles above.